Benzion Samueli

Dr. Benzion Samueli

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2020 in Annals of Diagnostic Pathology
Verified
Journal Article
Closed access
BSBenzion Samueli
Benzion Samueli
NSNeta Sror
Neta Sror
AJAlan Jotkowitz
Alan Jotkowitz
BTBenjamin Taragin
Benjamin Taragin

1 November 2020 in JCO Precision Oncology
Verified
Journal Article
Closed access
WKWaleed Kian
Waleed Kian
Laila C. RoismanLaila C. Roisman
Laila C. Roisman
IGIris M. Goldstein
Iris M. Goldstein
AAAbed Abo-Quider
Abed Abo-Quider
BSBenzion Samueli
Benzion Samueli
AYAlexander Yakobson
Alexander Yakobson

15 May 2020 in Molecular Genetics & Genomic Medicine
Verified
Journal Article
Open access
PDF file
MAMaram Arafat
Maram Arafat
AZAtif Zeadna
Atif Zeadna
ELEliahu Levitas
Eliahu Levitas
IVIris Har Vardi
Iris Har Vardi
BSBenzion Samueli
Benzion Samueli
RPRuti Parvari
Ruti Parvari
Background: Ubiquitin‐Specific Peptidase 26 (USP26), located on the X chromosome, encodes a deubiquitinating enzyme expressed mainly in testis, where it regulates protein turnover during spermatogenesis and modulates the ubiquitination levels of the Androgen Receptor (AR), and as a consequence, affects AR signaling.Methods: The patient was thoroughly characterized clinically. He was genetically tested by chromosome analysis and whole exome sequencing (WES).Results: The patient was diagnosed with Sertoli cell‐only syndrome pattern (SCOS). The WES analysis revealed only the variation in USP26: causing p.P469S in a highly evolutionary conserved amino acid as the possible cause for SCOS. The literature search identified 34 single variations and 14 clusters of variations in USP26 that were associated with male infertility. Only one of the 22 variations and of one cluster of three mutations tested for ubiquitination activity was found as damaging. Only one out of six variations tested for effect on AR function was found as damaging. Thus, the association of USP26 with male fertility was questioned.Conclusions: The finding in our patient and the discussion on the reviewed literature support a possible role for USP26 in male fertility.

12 December 2023 in Pathology - Research and Practice
Verified
Journal Article
Closed access
BSBenzion Samueli
Benzion Samueli
NANatalie Aizenberg
Natalie Aizenberg
RSRuthy Shaco-Levy
Ruthy Shaco-Levy
AKAviva Katzav
Aviva Katzav
YKYarden Kezerle
Yarden Kezerle
SASylvia L. Asa
Sylvia L. Asa

21 August 2022 in Applied Sciences
Verified
Journal Article
Open access
PDF file
ASAviad Sapir
Aviad Sapir
DKDaniel M. Kaplan
Daniel M. Kaplan
BSBenzion Samueli
Benzion Samueli
RNRosa Novoa
Rosa Novoa
OHOhad Hilly
Ohad Hilly
SESabri El-Saied
Sabri El-Saied
Background: IgG4-related disease (IgG4-RD) is an inflammatory process. The literature on IgG4-RD is rather limited, with mastoid involvement being uncommon. In such cases, presentation may mimic other middle ear and mastoid cavity pathologies. Objective: To summarize findings of patients with IgG4-RD involving the mastoid. Methods: Description of two new cases and summary of findings with previous reports. Results: Nineteen cases of IgG4-RD with mastoid bone involvement were reported in the literature, the earliest appearing at the beginning of the previous decade. Most frequent symptoms included hearing deterioration, tinnitus and otalgia. In 58% of the cases, the process was restricted to otologic manifestations. In 7 out of 19 cases, tissue IgG4 levels were elevated. In all histopathologic samples taken from the operative sites, a dense lymphoplasmacytic cell infiltration was observed. Following definitive pathological diagnosis, the most common treatment was corticosteroids. Generally, the time from onset to final diagnosis was usually more than six months. The treatment is corticosteroids, followed by immunosuppressive agents such as rituximab, cyclophosphamide, and methotrexate. Conclusions: IgG4-RD involving the mastoid is a challenging condition, both in diagnosis and treatment. Hence, IgG4-RD should be included in the differential diagnosis of middle ear pathologies and include a multi-disciplinary team for treatment.

7 February 2024 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
SDSharon Davidesko
Sharon Davidesko
MMMihai Meirovitz
Mihai Meirovitz
RSRuthy Shaco-Levy
Ruthy Shaco-Levy
SYShaked Yarza
Shaked Yarza
BSBenzion Samueli
Benzion Samueli
RKRoy Kessous
Roy Kessous